U.S. Markets closed

Amicus Therapeutics, Inc. (FOLD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
11.17-0.62 (-5.26%)
At close: 4:00PM EST

11.40 +0.23 (2.06%)
After hours: 7:44PM EST

Amicus Therapeutics, Inc.

3675 Market Street
Philadelphia, PA 19104
United States
215-921-7600
http://www.amicusrx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees584

Key Executives

NameTitlePayExercisedYear Born
Mr. John F. CrowleyChairman & CEO1.96M2.15M1967
Mr. Bradley L. Campbell M.B.A.Pres, COO & Director899.2k52.17k1976
Ms. Daphne E. QuimiChief Financial Officer630.45kN/A1966
Dr. Hung Viet DoChief Scientific Officer637.43k319.26k1968
Ms. Ellen S. RosenbergChief Legal Officer & Corp. Sec.686.59kN/A1963
Ms. Samantha ProutVP of Fin., Global Controller & Principal Accounting OfficerN/AN/A1978
Dr. Enrique DilonéSr. VP of Technical OperationsN/AN/A1967
Andrew FaughnanDirector of Investor RelationsN/AN/AN/A
Mr. Patrik S. FlorencioSr. VP, Global Chief Compliance & Risk OfficerN/AN/AN/A
Ms. Diana MooreHead of Global Corp. CommunicationsN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Philadelphia, Pennsylvania.

Corporate Governance

Amicus Therapeutics, Inc.’s ISS Governance QualityScore as of December 3, 2020 is 4. The pillar scores are Audit: 3; Board: 4; Shareholder Rights: 7; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.